Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-03-11
2010-06-08
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S093100
Reexamination Certificate
active
07732397
ABSTRACT:
Use of cardiotrophin in liver diseases. The invention describes the increased expression of cardiotrophin (CT-1) during the process of hepatic regeneration coinciding with maximum proliferation of hepatocytes and the role of CT-1 as a stimulator of hepatic regeneration. Furthermore, it describes the hepatoprotective role of CT-1 in various models of acute liver damage.The importance of using CT-1 in the manufacture of compositions for use in the treatment of hepatopathies is demonstrated. The invention describes such use in various forms and methods, including the recombinant protein and the use of the gene sequences that code for CT-1.
REFERENCES:
patent: 6719969 (2004-04-01), Hogaboam et al.
patent: 2002/0187936 (2002-12-01), Costa et al.
patent: WO 95/29237 (1995-11-01), None
patent: WO 00/43790 (2000-07-01), None
Jin et al. (1996) Cytokine, vol. 8 (12), 920-926.
Narayanan Menon et al. (2001) Mayo Clinic Proceedings, vol. 76 (10), 1021-1029.
Nagy et al. (2001) Hepatology, vol. 33(2), 339-345.
Reto A. Gadient, et al, “Leukemia Inhibitory Factor, Interleukin 6, and other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury”,Stem Cells. (1999) vol. 17; p. 127-137.
Michihisa Jougasaka, et al, “Augmented Cardiac Cardiotrophin-1 in Experimental Congestive Heart Failure”,Circulation 2000vol. 101; p. 14-17 (1999).
Shigemichi Hishinuma, et al, “Hypoxic Stress Induces Cardiotrophin-1 Expression in Cardiac Myocytes”,Biochemical and Biophysical Research Communicationsvol. 264, (1999) p. 436-440.
A. Stephanou, et al, “Cardiotrophin-1 Induces Heat Shock Protein Accumulation in Cultured Cardiac Cells and Protects them from Stressful Stimuli”,J Mol Cell Cardiolvol. 30, (1998) p. 849-855.
D. Pennica, et al, “Cardiotrophin-1, a Cytokine Present in Emboyronic Muscle, Supports Long-Term Survival of Spinal Motoneurons”,Neuronvol. 17 (1996) p. 63-74.
T. Border, et al, “Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy”,The Journal of clinical Investigationvol. 104, (1999) p. 1077-1085.
M. Bustos, et al, “Liver Damage using Suicide Genes”,American Journal of Pathology, vol. 157, (2000) p. 549-559.
T. Kishimoto, et al, “Cytokine Signal Transduction”,Cellvol. 76 (1994) p. 253-262.
M. Murakami, et al, “IL-6-Induced Homodimerization of gp 130 and Associated Activation of a Tyrosine Kinase”,Science, New Series vol. 260, (1993) p. 1808-1810.
S. Davis, et al, “LIFR# and gp130 as Heterodimerizing Signal Transducers of the Tripartite CNTF Receptor”,Science, New Series vol. 260 (1993) p. 1805-1808.
D. Pennica, et al, “Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy”,Proc. Natl,. Acad Sci. USAvol. 92 (1995) p. 1142-1146.
O. Robledo, et al, “Signaling of the Cardiotrophin-1 Receptor”,The Journal of Biological Chemical, (1997 vol. 272 p. 4855-4863.
Z. Sheng, et al, “Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival”,Developmentvol. 122 (1996) p. 419-428.
H. Jin, et al, “Effects of Cardiotrophin-1 on Haemodynamics and Cardiac Function in Conscious Rats”,Cytokinevol. 10 (1998) p. 19-25.
D. Latchman, “Cardiophin-1 (CT-1): a novel hypertropic and cardioprotective agent”,International Journal of Experimental Pathology, (1999) vol. 80 p. 189-196.
S. Haga, et al, Stat3 protects against Fas-induced liver injury by redox-dependent and—independent mechanisms,The Journal of Clinical Investigation(2003) vol. 112 p. 989-998.
M.J. Hussain, et al, “Cellular expression of tumour necrosis factor-α and interferon-γ in the liver biopsies of children with chronic liver disease”,Journal of Hepatology(1994) vol. 21 p. 816-821.
N. Kobayashi, et al, “Prevention of Acute Liver failure in Rats with Reversibly Immortalized Human Hepatocytes”,Science(2000) vol. 287 p. 1258-1262.
T. Kondo, et al, “Essential roles of the Fas ligand in the development of hepatitis”,Nature Medicine(1997) vol. 3 p. 409-413.
J.J. Lasarte, et al, “A Recombinant Adenovirus Encoding Hepatitis C Virus Core and E1 Proteins Protects Mice Against Cytokine-Induced Liver Damage”,Hepatology(2003) p. 461-470.
Y. Panis, et al, “Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection”,Surgeryvol. 121 (1997) p. 142-149.
N. Sheron, et al, “Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection”,Journal of Hepatology, vol. 12 (1991) p. 241-245.
U. Spengler, et al, “Serum Levels and in Situ Expression of TNF-α and TNF-α Binding Proteins in inflammatory liver diseases”,Cytokinevol. 8 (1996) p. 864-872.
G. Tergs et al, “A T Cell- dependent Experimental Liver Injury in Mice Inducible by Concanavalin A”,The American Society for Clinical Investigation, Inc. (1992) vol. 90, p. 196-203.
JH Hwan, et al, “Death receptor-mediated apoptosis and the liver”,Journal of Hepatology(2002) p. 400-410.
Peters, M. et al “A new hepatocyte stimulating factor: Cardiotrophin-1 (cT-1)” FEBS Letters, vol. 372, n°. 2-3, 1995 pp. 177-180.
Richard, C.D. et al “Mruine Cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells”. Journal of Interferon and Cytokine Research, vol. 16. n° 1, 1996 pp. 69-75.
Robledo O. et al “Hepatocyte-derived cell ilines express a functional receptor for cardiotrophin-1”. European Cytokine Network, vol. 8 n°. 3, 1997, pp. 45-252.
Hongkui, J. et al “In vivo effects of cardiotrophin-1”. Cytokine, vol. 8 n°. 12, 1996, pp. 920-926.
Webber et al., In Vivo Response of Hepatopcytes to Growth Factor Requires an Initial Priming Stimulus; Feb. 1994; pp. 489-497.
Bockhorn et al.; Vascular Endothelial Growth Factor Does Not Improve Liver Regeneration and Survival After 90% Subtotal Liver Resection; Hepatology Research 2007; 37: 353-359.
Journal of Hepatology 2000; Liver Regeneration; pp. 19-31, Fausto, N.
Ghezzi et al.; Erythropoietin as an Antiapoptotic, Tissue-Protective Cytokine; Cell Death and Differentiation (2004) 11, S37-S44.
Baixeras Llano Elena
Bustos De Abajo Matilde
Lasarte Sagastibelza Juan José
Prieto Valtueña Jesús
Ladas and Parry LLP
Proyecto de Biomedicina Cima, S.L.
Wehbe Anne Marie S
LandOfFree
Use of cardiotrophin in liver diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cardiotrophin in liver diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cardiotrophin in liver diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185332